BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2025 8:32:41 AM | Browse: 3 | Download: 1
 |
Received |
|
2025-07-03 13:03 |
|
Peer-Review Started |
|
2025-07-03 13:04 |
|
First Decision by Editorial Office Director |
|
2025-07-11 09:17 |
|
Return for Revision |
|
2025-07-11 09:17 |
|
Revised |
|
2025-07-23 15:49 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-27 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-27 08:42 |
|
Articles in Press |
|
2025-10-27 08:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-08 02:36 |
|
Publish the Manuscript Online |
|
2025-12-19 08:32 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Reevanshi Dhawan, Rakesh Mittal, Ashwani Kumar, Kuldip S Laller, Paramjeet S Gill, Adarsh Rag and Niti Mittal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Niti Mittal, Associate Professor, DM, Department of Pharmacology, PGIMS, Medical Road, Null, Rohtak 124001, Haryana, India. drnitimittal@uhsr.ac.in |
| Key Words |
Sacubitril/valsartan; Neprilysin inhibitor; N-terminal pro-B-type natriuretic peptide; High-sensitivity C-reactive protein; World Health Organisation Quality of Life Questionnaire; Heart failure |
| Core Tip |
This randomized clinical trial evaluated the efficacy and safety of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, as add-on to standard therapy compared to standard therapy alone in patients with New York Heart Association functional class II-III heart failure (HF). A total of 80 patients were enrolled out of which 25 patients in each group were available for per-protocol analysis. Baseline demographic, clinical and biochemical characteristics in both the groups were comparable. Sacubitril/valsartan demonstrated significant improvements in HF biomarkers, inflammation, and quality of life after 12 weeks without compromising safety supporting its role as an effective addition to standard HF therapy. |
| Publish Date |
2025-12-19 08:32 |
| Citation |
Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N. Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. World J Exp Med 2025; 15(4): 111542 |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i4/111542.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i4.111542 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
